- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02958839
Relationship Between Fibroblast Growth Factor 23 and Recurrence of Atrial Fibrillation After Catheter Ablation (REBECCA)
The Relationship Between Fibroblast Growth Factor 23 and the Recurrence of Atrial Fibrillation After Catheter Ablation: a Nested Case-Control Study
Studie Overzicht
Gedetailleerde beschrijving
Atrial fibrillation, which can result in stroke and thromboembolism in an approximately 5-fold increased risk, has been a great burden to health care system with the aging of population. Catheter ablation is the most promising treatment of atrial fibrillation. However, the recurrence rates of AF after catheter ablation are high, ranging from 20%-60%. Therefore, non-invasive predictors for AF recurrence after catheter ablation is necessary to select the optimal patients for this procedure.
Fibroblast growth factor-23 (FGF-23) is a bone-derived hormone that plays a central role in phosphate homeostasis. Recent study showed that fibroblast growth factor 23 plays an important role in cardiac remodeling and is considered to be independently associated with the occurrence of atrial fibrillation. In this study, we are going to observe the relationship between the serum FGF-23 and the arrythmia recurrence after catheter ablation of AF.
This research is going to recruit 200 consecutive patients with a history of atrial fibrillation for 180-360 days who intend to undergo catheter ablation. The day before catheter ablation, serum FGF-23 level will be detected. Echocardiogram and left atrial CT scan will also be performed on the day before catheter ablation. All patients will be routinely follow up in the outpatient department by cardiologists every month for 1 year. If patients complain about palpitations, fatigue, or other symptoms related to arrhythmia, Holter monitoring will be performed. Patients will also be advised to see their doctor anytime they have these symptoms and to undergo a 12-lead ECG examination or 24-hour Holter monitoring. In asymptomatic patients, 24-hour Holter monitoring or 7-day cardiac event recording will be performed every three months after the procedure. The endpoint for follow-up is the recurrence of atrial fibrillation, which is considered to be any episode of AF/AFL/AT after a blank period of 3 months after the procedure of catheter ablation. Those who develop recurrence of AF during follow up will be assigned to recurrence group, and those who do not develop recurrence of AF during follow up will be assigned to non-recurrence group. Comparison of the serum FGF-23 level between the two groups will be carried out in order to investigate the relationship between serum FGF-23 level and the recurrence of AF.
Studietype
Inschrijving (Verwacht)
Contacten en locaties
Studie Locaties
-
-
Beijing
-
Beijing, Beijing, China, 100019
- Peking University Third Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Have a history of atrial fibrillation for 180 to 360 days
- Provide written informed consent, having understood the benefits and risks of participation in the trial
Exclusion Criteria:
- Significant structural heart disease (including symptomatic coronary heart disease; prosthetic mitral or tricuspid valve; congenital heart disease where abnormality or its correction prohibits or increases the risk of ablation)
- Atrial Fibrillation precipitated by other diseases (such as thyrotoxicosis)
- Severe dysfunction of liver or kidney
- Diabetes
- Malignant tumor
- Inability or refusal to provide written informed consent for the study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: Case-control
- Tijdsperspectieven: Prospectief
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
---|---|
Recurrence Group
In the case control trial, patients who have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
|
Patients with persistent or paroxysmal atrial fibrillation will go through catheter ablation
|
Non-recurrence Group
In the case control trial, patients who do not have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
|
Patients with persistent or paroxysmal atrial fibrillation will go through catheter ablation
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Incidence of the recurrence of atrial fibrillation
Tijdsspanne: after 3 months from the procedure of catheter ablation
|
The recurrence of atrial fibrillation is considered to be any episode of AF/AFL/AT after a blank period of 3 months after the procedure of catheter ablation
|
after 3 months from the procedure of catheter ablation
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Plasma fibroblast growth factor 23 levels
Tijdsspanne: after 3 months from the procedure of catheter ablation
|
Fibroblast Growth Factor 23 plays an important role in cardiac remodeling and is considered to be independently associated with the occurrence of atrial fibrillation
|
after 3 months from the procedure of catheter ablation
|
CHA2DS2-VASc score
Tijdsspanne: after 3 months from the procedure of catheter ablation
|
CHA2DS2-VASc score is used to measure the risk of thrombotic event in patient with atrial fibrillation
|
after 3 months from the procedure of catheter ablation
|
Cardiac CT evaluation
Tijdsspanne: after 3 months from the procedure of catheter ablation
|
To evaluate the degree of fibrosis of the left and right atrium and pulmonary veins
|
after 3 months from the procedure of catheter ablation
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Lei Li, MD, Peking University Third Hospital
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- L03-ZZK-FGF23
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Catheter ablation
-
Boston Scientific CorporationActief, niet wervendBoezemfibrillerenNederland, Spanje, Hongkong, Hongarije, Duitsland, Frankrijk, Australië, Israël, Maleisië, Ierland, België, Verenigd Koninkrijk, Oostenrijk, Portugal, Griekenland, Saoedi-Arabië, Tsjechië, Finland, Italië, Monaco, Polen
-
St. Luke's-Roosevelt Hospital CenterVoltooidArterioveneuze misvorming van de hersenen | Hersenvasculaire misvormingen | Ader van Galen misvormingVerenigde Staten
-
Abbott Medical DevicesVoltooidNiet-paroxysmale boezemfibrilleren | Linker atriale tachycardieHongkong, Australië, Italië, Duitsland, Frankrijk
-
Ospedale San DonatoOnbekend
-
National Institute of Cardiovascular Diseases,...MedtronicWervingST-segment elevatie myocardinfarct (STEMI) | Totale occlusie van kransslagader | Primaire percutane coronaire interventiePakistan
-
Lepu Medical Technology (Beijing) Co., Ltd.Aanmelden op uitnodigingCoronaire verkalkte ziekteChina
-
Gulhane School of MedicineVoltooidPijn, postoperatief | Anesthesie | Artropathie van de knie | Verstopping van de katheterKalkoen
-
Yonsei UniversityOnbekend
-
University of LeipzigVoltooid
-
Medtronic VascularVoltooidOngecontroleerde hypertensieVerenigde Staten